Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that two year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Mee